Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases. It is also developing a pipeline of bispecific antibody candidates using its heterodimer Fc bispecific technology: XmAb14045, which is in a Phase I trial for the treatment of acute myeloid leukemia (AML); XmAb13676, which is in a Phase I trial for the treatment of B-cell malignancies; XmAb18087, which is in preclinical development for the treatment of neuroendocrine tumors, and XmAb20717, which is in preclinical development for the treatment of various cancers and is its dual checkpoint inhibitor.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:XNCR
- CUSIP: N/A
- Web: www.xencor.com/
Capitalization:- Market Cap: $1.07 billion
- Outstanding Shares: 46,703,000
Average Prices:- 50 Day Moving Avg: $21.71
- 200 Day Moving Avg: $23.23
- 52 Week Range: $18.10 - $29.38
P/E:- Trailing P/E Ratio: 66.91
- Foreward P/E Ratio: -16.20
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $84.61 million
- Price / Sales: 12.70
- Book Value: $6.51 per share
- Price / Book: 3.53
Profitability:- EBIDTA: $15.7 million
- Net Margins: -337.21%
- Return on Equity: -19.01%
- Return on Assets: -13.86%
Debt:- Current Ratio: 1.55%
- Quick Ratio: 1.55%
Misc:- Average Volume: 242,392 shs.
- Beta: 2.13
- Short Ratio: 8.3
Frequently Asked Questions for Xencor (NASDAQ:XNCR)
What is Xencor's stock symbol?
Xencor trades on the NASDAQ under the ticker symbol "XNCR."
How were Xencor's earnings last quarter?
Xencor Inc (NASDAQ:XNCR) posted its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.31) EPS for the quarter, missing the Zacks' consensus estimate of ($0.25) by $0.06. The company had revenue of $4.34 million for the quarter, compared to analyst estimates of $8.15 million. Xencor had a negative net margin of 337.21% and a negative return on equity of 19.01%. View Xencor's Earnings History.
When will Xencor make its next earnings announcement?
Where is Xencor's stock going? Where will Xencor's stock price be in 2017?
6 brokerages have issued twelve-month price targets for Xencor's shares. Their predictions range from $21.00 to $35.00. On average, they expect Xencor's share price to reach $28.60 in the next year. View Analyst Ratings for Xencor.
What are analysts saying about Xencor stock?
Here are some recent quotes from research analysts about Xencor stock:
- 1. According to Zacks Investment Research, "Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California. " (4/29/2017)
- 2. Instinet analysts commented, "We are initiating on XNCR with a Neutral rating and a $21 target price. We recommend stepping to the sidelines in 2017, as we anticipate that XNCR shares will trade flat relative to the biotechnology index over the next 12 months. We note that several near-term catalysts are likely already 'baked in' the current valuation, particularly for the '5871 IgG4- RD program. We believe that a key catalyst'meaningful data for XNCR's bispecific assets'is likely to lead to upside, but that it will occur beyond our 12-month horizon." (3/1/2017)
Who are some of Xencor's key competitors?
Some companies that are related to Xencor include Spark Therapeutics (ONCE), Loxo Oncology (LOXO), Aerie Pharmaceuticals (AERI), Radius Health (RDUS), Lexicon Pharmaceuticals (LXRX), Halozyme Therapeutics (HALO), NovoCure Limited (NVCR), Array BioPharma (ARRY), Acceleron Pharma (XLRN), Dermira (DERM), Amarin Corporation PLC (AMRN), Clinigen Group PLC (CLIN), Insmed (INSM), Acorda Therapeutics (ACOR), Synergy Pharmaceuticals (SGYP), Omeros Corporation (OMER), Aduro Biotech (ADRO) and Insys Therapeutics (INSY).
Who are Xencor's key executives?
Xencor's management team includes the folowing people:
- Bruce L.A. Carter Ph.D., Independent Chairman of the Board
- Bassil I. Dahiyat Ph.D., President, Chief Executive Officer, Founder, Director
- John R. Desjarlais Ph.D., Senior Vice President, Research and Chief Scientific Officer
- Paul Foster M.D., Senior Vice President, Chief Medical Officer
- John J. Kuch, Vice President - Finance
- Edgardo Baracchini Jr. Ph.D., Chief Business Officer
- A. Bruce Montgomery M.D., Lead Independent Director
- Robert F. Baltera Jr., Independent Director
- Kevin C. Gorman Ph.D., Independent Director
- Kurt A. Gustafson, Independent Director
Who owns Xencor stock?
Xencor's stock is owned by a number of of institutional and retail investors. Top institutional investors include Creative Planning (0.08%) and Equitec Specialists LLC (0.01%). Company insiders that own Xencor stock include Bassil I Dahiyat, Bruce L A Carter, Edgardo Baracchini Jr, Edgardo Baracchini, Jr, John J Kuch, John R Desjarlais, John S Stafford III and Paul A Foster. View Institutional Ownership Trends for Xencor.
Who sold Xencor stock? Who is selling Xencor stock?
Xencor's stock was sold by a variety of institutional investors in the last quarter, including Creative Planning. Company insiders that have sold Xencor stock in the last year include Bassil I Dahiyat, Bruce L A Carter, Edgardo Baracchini Jr, Edgardo Baracchini, Jr, John J Kuch, John R Desjarlais and John S Stafford III. View Insider Buying and Selling for Xencor.
Who bought Xencor stock? Who is buying Xencor stock?
How do I buy Xencor stock?
Shares of Xencor can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Xencor's stock price today?
One share of Xencor stock can currently be purchased for approximately $23.00.
MarketBeat Community Rating for Xencor (NASDAQ XNCR)MarketBeat's community ratings are surveys of what our community members think about Xencor and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Xencor (NASDAQ:XNCR) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Hold Ratings, 4 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.67) |
| Consensus Price Target: | $28.60 (24.35% upside) |
Analysts' Ratings History for Xencor (NASDAQ:XNCR)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 6/16/2017 | Wedbush | Reiterated Rating | Outperform | $29.00 | Low |  |
| 3/1/2017 | Instinet | Initiated Coverage | Neutral -> Neutral | $21.00 | N/A | |
| 3/1/2017 | Nomura | Initiated Coverage | Neutral | | N/A | |
| 11/28/2016 | Canaccord Genuity | Set Price Target | Buy | $32.00 | N/A | |
| 11/3/2016 | Leerink Swann | Reiterated Rating | Buy | $26.00 | N/A | |
| 10/4/2016 | Piper Jaffray Companies | Initiated Coverage | Overweight | $35.00 | N/A | |
| 5/2/2016 | Oppenheimer Holdings, Inc. | Reiterated Rating | Buy | | N/A | |
| 12/22/2015 | FBR & Co | Reiterated Rating | Buy | $20.00 | N/A | |
| 8/5/2015 | MLV & Co. | Reiterated Rating | Buy | $22.00 -> $29.00 | N/A | |
(Data available from 7/20/2015 forward)
Earnings History for Xencor (NASDAQ:XNCR)Earnings History by Quarter for Xencor (NASDAQ XNCR)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 7/31/2017 | | ($0.28) | | | | | N/A | |
| 5/9/2017 | Q1 2017 | ($0.25) | ($0.31) | $8.15 million | $4.34 million | View | Listen | |
| 8/2/2016 | Q216 | ($0.18) | $1.13 | $7.43 million | $66.00 million | View | N/A | |
| 5/2/2016 | Q116 | ($0.27) | ($0.16) | $3.50 million | $7.30 million | View | N/A | |
| 3/7/2016 | Q415 | ($0.30) | $0.19 | $2.50 million | $21.80 million | View | N/A | |
| 11/3/2015 | Q315 | ($0.17) | ($0.25) | $3.57 million | $3.50 million | View | N/A | |
| 8/4/2015 | Q215 | ($0.18) | ($0.22) | $1.90 million | $1.01 million | View | N/A | |
| 5/4/2015 | Q115 | ($0.17) | ($0.19) | $1.90 million | $1.49 million | View | Listen | |
| 2/19/2015 | | ($0.22) | ($0.04) | $1.33 million | $5.66 million | View | N/A | |
| 11/10/2014 | Q3 14 | ($0.19) | ($0.20) | $1.50 million | $0.85 million | View | N/A | |
| 7/31/2014 | | ($0.19) | ($0.16) | | $0.82 million | View | N/A | |
| 5/14/2014 | Q1 14 | ($0.16) | ($0.12) | $1.71 million | $2.20 million | View | N/A | |
| 3/19/2014 | Q413 | ($0.14) | ($0.24) | $1.71 million | $1.70 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Xencor (NASDAQ:XNCR)2017 EPS Consensus Estimate: ($0.92)
2018 EPS Consensus Estimate: ($1.70)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($0.22) | ($0.17) | ($0.20) |
| Q2 2017 | 2 | ($0.29) | ($0.19) | ($0.24) |
| Q3 2017 | 2 | ($0.32) | ($0.20) | ($0.26) |
| Q4 2017 | 2 | ($0.24) | ($0.21) | ($0.23) |
| Q1 2018 | 1 | ($0.39) | ($0.39) | ($0.39) |
| Q2 2018 | 1 | ($0.41) | ($0.41) | ($0.41) |
| Q3 2018 | 1 | ($0.44) | ($0.44) | ($0.44) |
| Q4 2018 | 1 | ($0.46) | ($0.46) | ($0.46) |
(Data provided by Zacks Investment Research)
Dividend History for Xencor (NASDAQ:XNCR)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Xencor (NASDAQ:XNCR)Insider Ownership Percentage: 4.03%
Institutional Ownership Percentage: 75.00%
Insider Trades by Quarter for Xencor (NASDAQ:XNCR)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/28/2017 | John S Stafford III | Major Shareholder | Buy | 6,000 | $19.94 | $119,640.00 | |
| 6/16/2017 | John S Stafford III | Major Shareholder | Buy | 1,500 | $19.67 | $29,505.00 | |
| 6/14/2017 | Bruce L A Carter | Director | Sell | 20,000 | $20.61 | $412,200.00 | |
| 6/2/2017 | Bruce L A Carter | Director | Sell | 2,366 | $22.00 | $52,052.00 | |
| 5/26/2017 | Bruce L A Carter | Director | Sell | 12,400 | $22.19 | $275,156.00 | |
| 5/2/2017 | Edgardo Baracchini Jr | Insider | Sell | 10,568 | $26.01 | $274,873.68 | |
| 4/27/2017 | Edgardo Baracchini Jr | Insider | Sell | 904 | $26.04 | $23,540.16 | |
| 3/16/2017 | John J. Kuch | VP | Sell | 15,000 | $24.42 | $366,300.00 | |
| 3/8/2017 | Edgardo Baracchini Jr | Insider | Sell | 1,821 | $25.00 | $45,525.00 | |
| 12/6/2016 | John S Stafford III | Major Shareholder | Sell | 63,061 | $27.71 | $1,747,420.31 | |
| 9/28/2016 | Edgardo Baracchini Jr | Insider | Sell | 10,000 | $25.35 | $253,500.00 | |
| 9/27/2016 | John S Stafford III | Major Shareholder | Sell | 40,000 | $25.72 | $1,028,800.00 | |
| 9/2/2016 | Edgardo Baracchini Jr | Insider | Sell | 10,000 | $21.06 | $210,600.00 | |
| 8/30/2016 | Bassil I Dahiyat | Insider | Sell | 40,000 | $21.80 | $872,000.00 | |
| 8/26/2016 | John S Stafford III | Major Shareholder | Sell | 24,351 | $21.48 | $523,059.48 | |
| 8/24/2016 | John J Kuch | VP | Sell | 25,000 | $21.95 | $548,750.00 | |
| 8/23/2016 | John R Desjarlais | VP | Sell | 16,294 | $21.73 | $354,068.62 | |
| 8/23/2016 | John S Stafford III | Major Shareholder | Sell | 96,828 | $21.73 | $2,104,072.44 | |
| 8/16/2016 | Bassil I Dahiyat | Insider | Sell | 45,886 | $22.06 | $1,012,245.16 | |
| 8/15/2016 | Bruce L A Carter | Director | Sell | 3,400 | $22.67 | $77,078.00 | |
| 8/15/2016 | John S Stafford III | Major Shareholder | Sell | 10,000 | $23.06 | $230,600.00 | |
| 8/11/2016 | John S Stafford III | Major Shareholder | Sell | 30,500 | $21.87 | $667,035.00 | |
| 8/10/2016 | Edgardo Baracchini Jr | Insider | Sell | 2,500 | $21.83 | $54,575.00 | |
| 8/3/2016 | Edgardo Baracchini, Jr. | Insider | Sell | 4,528 | $20.00 | $90,560.00 | |
| 8/3/2016 | John R. Desjarlais | VP | Sell | 5,905 | $20.00 | $118,100.00 | |
| 7/11/2016 | Edgardo Baracchini Jr | Insider | Sell | 1,250 | $18.13 | $22,662.50 | |
| 6/28/2016 | Edgardo Baracchini Jr | Insider | Sell | 1,250 | $15.10 | $18,875.00 | |
| 5/24/2016 | Bassil I Dahiyat | CEO | Sell | 45,886 | $13.00 | $596,518.00 | |
| 4/7/2016 | Edgardo Baracchini Jr | Insider | Sell | 3,750 | $15.00 | $56,250.00 | |
| 3/17/2016 | Bassil I Dahiyat | CEO | Sell | 45,886 | $11.02 | $505,663.72 | |
| 3/3/2016 | John R Desjarlais | VP | Sell | 14,260 | $12.01 | $171,262.60 | |
| 2/1/2016 | John S Stafford III | Major Shareholder | Sell | 25 | $10.79 | $269.75 | |
| 1/29/2016 | John S Stafford III | Major Shareholder | Buy | 25 | $10.83 | $270.75 | |
| 1/4/2016 | John R. Desjarlais | VP | Sell | 1,100 | $14.13 | $15,543.00 | |
| 12/17/2015 | John J Kuch | VP | Sell | 4,781 | $14.89 | $71,189.09 | |
| 12/16/2015 | Paul A. Foster | insider | Sell | 6,025 | $15.01 | $90,435.25 | |
| 12/3/2015 | John S. Stafford III | Director | Sell | 30,000 | $15.13 | $453,900.00 | |
| 11/25/2015 | Edgardo Baracchini, Jr. | insider | Sell | 2,500 | $15.00 | $37,500.00 | |
| 9/3/2015 | John S Stafford III | Director | Sell | 10,000 | $17.22 | $172,200.00 | |
| 9/1/2015 | Edgardo Baracchini, Jr. | insider | Sell | 1,250 | $16.49 | $20,612.50 | |
| 7/6/2015 | John S Stafford III | Director | Sell | 10,000 | $22.29 | $222,900.00 | |
| 7/1/2015 | Edgardo Baracchini Jr | Insider | Sell | 2,500 | $22.24 | $55,600.00 | |
| 6/16/2015 | John S Stafford III | Director | Sell | 20,000 | $20.35 | $407,000.00 | |
| 6/15/2015 | Bruce L A Carter | Director | Sell | 10,000 | $19.21 | $192,100.00 | |
| 6/15/2015 | Edgardo Baracchini Jr | Insider | Sell | 1,277 | $19.85 | $25,348.45 | |
| 6/12/2015 | John J Kuch | VP | Sell | 8,756 | $19.35 | $169,428.60 | |
| 6/12/2015 | John S Stafford III | Director | Sell | 250,000 | $19.00 | $4,750,000.00 | |
| 6/3/2015 | John S Stafford III | Director | Sell | 10,000 | $18.76 | $187,600.00 | |
| 6/1/2015 | Edgardo Baracchini Jr | Insider | Sell | 1,250 | $18.14 | $22,675.00 | |
| 5/26/2015 | John S Stafford III | Director | Sell | 10,000 | $17.01 | $170,100.00 | |
| 5/15/2015 | Edgardo Baracchini Jr | Insider | Sell | 1,604 | $15.00 | $24,060.00 | |
| 8/11/2014 | John S Stafford III | Director | Sell | 124,000 | $9.37 | $1,161,880.00 | |
| 12/6/2013 | John S Stafford III | Director | Buy | 275,000 | $5.50 | $1,512,500.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Xencor (NASDAQ:XNCR)
Latest Headlines for Xencor (NASDAQ:XNCR)
| Source: |
|
| Date | Headline |
|---|
 | Zacks: Analysts Expect Xencor Inc (XNCR) Will Post Earnings of -$0.25 Per Share
www.americanbankingnews.com - July 20 at 6:24 PM |
 | Xencor, Inc. breached its 50 day moving average in a Bullish Manner : XNCR-US : July 6, 2017
finance.yahoo.com - July 6 at 3:26 PM |
| Xencor, Inc. (XNCR) Major Shareholder John S. Stafford III Acquires 6,000 Shares
www.americanbankingnews.com - June 30 at 7:29 PM |
| Xencor, Inc. (XNCR) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - June 30 at 11:05 AM |
| Xencor, Inc. (XNCR) Expected to Post Quarterly Sales of $8.15 Million
www.americanbankingnews.com - June 28 at 11:10 AM |
| -$0.25 EPS Expected for Xencor, Inc. (XNCR) This Quarter
www.americanbankingnews.com - June 26 at 4:12 PM |
| Xencor, Inc. (XNCR) Major Shareholder Purchases $29,505.00 in Stock
www.americanbankingnews.com - June 20 at 7:50 PM |
 | FDA Nod For Ipsen, XNCR On Watch, Results MAGNIFY CELG's R2 Regimen
www.rttnews.com - June 19 at 8:06 AM |
 | FDA Nod For Ipsen, XNCR On Watch, Results MAGINIFY CELG's R2 Regimen
www.nasdaq.com - June 18 at 7:58 PM |
 | Xencor (XNCR) Reports Interim Data from an Ongoing Open-Label Phase 2 Study of XmAb5871 in IgG4-Related Disease
www.streetinsider.com - June 18 at 12:10 AM |
| Xencor Presents Interim Data from an Ongoing, Open-label, Phase 2 Study of XmAb®5871 in IgG4-Related Disease at EULAR 2017
finance.yahoo.com - June 17 at 7:49 AM |
| Insider Selling: Xencor, Inc. (XNCR) Director Sells 20,000 Shares of Stock
www.americanbankingnews.com - June 16 at 7:34 PM |
| Xencor's (XNCR) "Outperform" Rating Reiterated at Wedbush
www.americanbankingnews.com - June 16 at 4:22 PM |
| ETFs with exposure to Xencor, Inc. : June 12, 2017
finance.yahoo.com - June 12 at 8:15 PM |
| Xencor, Inc. :XNCR-US: Earnings Analysis: Q1, 2017 By the Numbers : June 9, 2017
finance.yahoo.com - June 10 at 3:41 AM |
| Xencor Appoints Raphael Clynes, M.D., Ph.D., as Vice President of Translational Biology
finance.yahoo.com - June 9 at 2:48 AM |
| Bruce L. A. Carter Sells 2,366 Shares of Xencor Inc (XNCR) Stock
www.americanbankingnews.com - June 6 at 8:40 PM |
| Xencor Inc (XNCR) Given Outperform Rating at Wedbush
www.americanbankingnews.com - June 6 at 4:20 PM |
| Xencor Inc (XNCR) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - June 5 at 11:10 AM |
| Analysts Expect Xencor Inc (XNCR) Will Post Quarterly Sales of $8.15 Million
www.americanbankingnews.com - June 2 at 1:48 PM |
| Bruce L. A. Carter Sells 12,400 Shares of Xencor Inc (XNCR) Stock
www.americanbankingnews.com - May 31 at 10:26 PM |
| -$0.25 Earnings Per Share Expected for Xencor Inc (XNCR) This Quarter
www.americanbankingnews.com - May 31 at 10:26 AM |
| Xencor to Present at Jefferies 2017 Global Healthcare Conference
finance.yahoo.com - May 30 at 8:06 AM |
| Worst-Performing Gurus' Stocks
finance.yahoo.com - May 24 at 8:04 AM |
| Q2 2017 EPS Estimates for Xencor Inc Lowered by Analyst (XNCR)
www.americanbankingnews.com - May 12 at 7:50 AM |
| Xencor Inc (XNCR) to Post Q2 2017 Earnings of ($0.29) Per Share, Wedbush Forecasts
www.americanbankingnews.com - May 12 at 7:50 AM |
| Xencor (XNCR) Announces Orphan Drug Designation from FDA for XmAb5871 to Treat IgG4-Related Disease
www.streetinsider.com - May 11 at 3:20 PM |
| Xencor's Lead Drug Candidate, XmAb5871, Receives Orphan Drug Designation from FDA for Treatment of IgG4-Related Disease
finance.yahoo.com - May 11 at 3:20 PM |
| Edited Transcript of XNCR earnings conference call or presentation 9-May-17 8:30pm GMT
finance.yahoo.com - May 11 at 3:46 AM |
| Xencor Inc (XNCR) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 10 at 5:18 PM |
| Investor Network: Xencor, Inc. to Host Earnings Call
finance.yahoo.com - May 10 at 9:38 AM |
| Xencor Inc (XNCR) Rating Reiterated by Wedbush
www.americanbankingnews.com - May 10 at 9:18 AM |
| Xencor reports 1Q loss
finance.yahoo.com - May 9 at 8:16 PM |
| Xencor Inc (XNCR) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 9 at 10:31 AM |
| Xencor, Inc. breached its 50 day moving average in a Bearish Manner : XNCR-US : May 9, 2017
finance.yahoo.com - May 9 at 9:29 AM |
| Xencor Inc (XNCR) Expected to Post Quarterly Sales of $8.15 Million
www.americanbankingnews.com - May 7 at 8:16 AM |
| Xencor Inc (XNCR) to Release Earnings on Tuesday
www.americanbankingnews.com - May 7 at 7:20 AM |
| Analysts Anticipate Xencor Inc (XNCR) Will Post Earnings of -$0.25 Per Share
www.americanbankingnews.com - May 5 at 12:18 PM |
| Xencor (XNCR) Given Daily Media Sentiment Rating of 0.17
www.americanbankingnews.com - May 3 at 4:26 PM |
| Insider Selling: Xencor Inc (XNCR) Insider Sells 10,568 Shares of Stock
www.americanbankingnews.com - May 2 at 9:54 PM |
| Xencor to Host First Quarter 2017 Financial Results Webcast and Conference Call on May 9, 2017
finance.yahoo.com - May 2 at 8:08 AM |
| Somewhat Favorable News Coverage Somewhat Unlikely to Affect Xencor (XNCR) Stock Price
www.americanbankingnews.com - April 30 at 8:45 AM |
| Xencor Inc (XNCR) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - April 29 at 7:26 AM |
| Xencor Inc (XNCR) to Release Earnings on Monday
www.americanbankingnews.com - April 29 at 7:10 AM |
| Insider Selling: Xencor Inc (XNCR) Insider Sells 904 Shares of Stock
www.americanbankingnews.com - April 27 at 9:56 PM |
| Xencor (XNCR) Receives Media Impact Rating of 0.31
www.americanbankingnews.com - April 27 at 8:34 AM |
| Xencor, Inc. – Value Analysis (NASDAQ:XNCR) : April 26, 2017
finance.yahoo.com - April 26 at 5:22 PM |
| Xencor to Present at 42nd Annual Deutsche Bank Health Care Conference
finance.yahoo.com - April 26 at 8:11 AM |
| Xencor, Inc. breached its 50 day moving average in a Bullish Manner : XNCR-US : April 25, 2017
finance.yahoo.com - April 25 at 7:39 PM |
| Somewhat Favorable News Coverage Extremely Likely to Affect Xencor (XNCR) Stock Price
www.americanbankingnews.com - April 23 at 11:49 AM |
Xencor (XNCR) Chart for Thursday, July, 20, 2017
